Despite laying the groundwork for coverage by the National Health Service (EOYY), predictive biomarker testing for Homologous Recombination Deficiency (HRD) remains inaccessible to women with advanced ovarian cancer in Greece. HRD testing is a crucial component of personalized medicine, identifying patients most likely to benefit from specific treatments. The implementation is currently blocked due to insufficient legislative formulation surrounding reimbursement procedures. While the foundations for compensation through the EOYY exist, a clear legal framework is needed to enable practical application. This delay hinders access to potentially life-saving, targeted therapies. Experts emphasize the importance of these biomarkers in modern oncology and the need to resolve the legal obstacles promptly. The situation presents a paradox, as the potential benefits of this advanced testing are currently unrealized.